644 related articles for article (PubMed ID: 15273335)
21. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma.
Kotzerke J; Guhlmann A; Moog F; Frickhofen N; Reske SN
Eur J Nucl Med; 1999 Jan; 26(1):31-8. PubMed ID: 9933659
[TBL] [Abstract][Full Text] [Related]
22. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
23. Staging in childhood lymphoma: differences between FDG-PET and CT.
Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C
Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722
[TBL] [Abstract][Full Text] [Related]
24. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
25. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma.
Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P
Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087
[TBL] [Abstract][Full Text] [Related]
26. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
27. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U
Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
[TBL] [Abstract][Full Text] [Related]
29. Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study.
Picardi M; Soricelli A; Pane F; Zeppa P; Nicolai E; De Laurentiis M; Grimaldi F; Rotoli B
Radiology; 2009 May; 251(2):574-82. PubMed ID: 19401581
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
31. Can diffusion-weighted whole-body MRI replace contrast-enhanced CT for initial staging of Hodgkin lymphoma in children and adolescents?
Regacini R; Puchnick A; Luisi FAV; Lederman HM
Pediatr Radiol; 2018 May; 48(5):638-647. PubMed ID: 29362839
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
[TBL] [Abstract][Full Text] [Related]
33. Restaging of patients with lymphoma. Comparison of low dose CT (20 mAs) with contrast enhanced diagnostic CT in combined [18F]-FDG PET/CT.
la Fougère C; Pfluger T; Schneider V; Hacker M; Bröckel N; Morhard D; Hundt W; Bartenstein P; Becker C; Tiling R
Nuklearmedizin; 2008; 47(1):37-42. PubMed ID: 18278211
[TBL] [Abstract][Full Text] [Related]
34. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow disease detection with FDG-PET/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study.
Pelosi E; Penna D; Douroukas A; Bellò M; Amati A; Arena V; Passera R; Bisi G
Q J Nucl Med Mol Imaging; 2011 Aug; 55(4):469-75. PubMed ID: 21150862
[TBL] [Abstract][Full Text] [Related]
36. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Buchmann I; Reinhardt M; Elsner K; Bunjes D; Altehoefer C; Finke J; Moser E; Glatting G; Kotzerke J; Guhlmann CA; Schirrmeister H; Reske SN
Cancer; 2001 Mar; 91(5):889-99. PubMed ID: 11251940
[TBL] [Abstract][Full Text] [Related]
37. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
[TBL] [Abstract][Full Text] [Related]
38. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.
Tatsumi M; Cohade C; Nakamoto Y; Fishman EK; Wahl RL
Radiology; 2005 Dec; 237(3):1038-45. PubMed ID: 16304117
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography scanning in the assessment of patients with lymphoma.
Foo SS; Mitchell PL; Berlangieri SU; Smith CL; Scott AM
Intern Med J; 2004 Jul; 34(7):388-97. PubMed ID: 15271172
[TBL] [Abstract][Full Text] [Related]
40. 18F-FDG-PET/CT in the surveillance of patients with lymphoma: detection of asymptomatic recurrences.
García Vicente AM; Bellón Guardia M; Soriano Castrejón A; Calle Primo C; Cordero García JM; Palomar Muñoz A; Pilkington Woll JP; Talavera Rubio MP; Hernández Ruiz B
Rev Esp Med Nucl Imagen Mol; 2012; 31(1):22-7. PubMed ID: 21742419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
